Viracta Up 5% After It Reacquires Rights to Combination Therapy in China
August 23 2021 - 11:15AM
Dow Jones News
By Michael Dabaie
Viracta Therapeutics Inc. shares were up 5% to $9.51 after the
company said it reacquired the rights to its combination therapy in
China.
The oncology company targeting virus-associated malignancies
said it reacquired the exclusive rights to develop and
commercialize its all-oral combination product candidate in China
previously licensed to Shenzhen Salubris Pharmaceuticals Co. The
rights were returned to Viracta in exchange for a $4 million cash
payment to Salubris.
Viracta's combination therapy of nanatinostat and valganciclovir
is currently in a Phase 2 trial for Epstein-Barr virus-positive
lymphoma.
Viracta also received U.S. Food and Drug Administration
clearance of an investigational new drug application for a Phase
1b/2 trial of the combination therapy in EBV(+) recurrent or
metastatic nasopharyngeal carcinoma and other EBV(+) solid
tumors.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
August 23, 2021 11:02 ET (15:02 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From Apr 2023 to Apr 2024